Arca
Skip to content
Tools
Tools

PGF: Placenta growth factor

Growth factor active in angiogenesis and endothelial cell growth, stimulating their proliferation and migration.

  • Drugs that act on it: 3
  • Approved: 1
  • In phases 1 to 3: 2
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on PGF, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 2
  • Other 1

Approved1

  • Aflibercept

Phase 31

  • Conbercept

Phase 21

  • TB-403

Phase 10

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Placenta growth factor inhibitor.
    AfliberceptApprovedOllin BiosciencesProtein or peptideInhibitor102
    ConberceptPhase 3Chengdu Kanghong Biotech Co., Ltd.Protein or peptideInhibitor6
    TB-403Phase 2BioInvent International ABOtherInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 14 in all, from ClinicalTrials.gov.
    A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Macular Edema After Retinal Vein Occlusion (MK-8748-006)AfliberceptPhase 2 / Phase 3Not yet recruitingMerck Sharp & Dohme LLCNov 20, 2026
    Observation on the Efficacy of Aflibercept 8mg Intravitreal Injection Solution on Retinal Fluid in nAMD Patients With PEDAfliberceptPhase 4Not yet recruitingHonghua Yu,MDNov 17, 2026
    Efficacy of Aflibercept With Sequential Laser Photocoagulation for Macular Edema Secondary to Retinal Artery Macroaneurysm.Aflibercept—Not yet recruitingNew Valley UniversityNov 6, 2026
    VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) StudyAfliberceptPhase 2Not yet recruitingUniversity of MiamiOct 23, 2026
    A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).AfliberceptPhase 3Recruiting4D Molecular TherapeuticsOct 9, 2026
    A Study to Compare GNR-139 and Eylea® in Patients With nAMDAfliberceptPhase 3RecruitingAO GENERIUMSep 28, 2026
    Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02)AfliberceptPhase 3Not yet recruitingOllin Biosciences, Inc.Sep 25, 2026
    Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03)AfliberceptPhase 3Not yet recruitingOllin Biosciences, Inc.Sep 25, 2026
    LEAP Strategy for Neovascular Age-Related Macular DegenerationConberceptNot applicableNot yet recruitingChinese PLA General HospitalAug 4, 2026
    A Study on the Combination of Tongluo Huayu Formula in Treating RVO of Phlegm-Stasis Intertwinement Type: Based on the Mechanism of Systemic Metabolic Regulation Mediated by Gut MicrobiotaConberceptNot applicableNot yet recruitingFirst Affiliated Hospital of Zhejiang UniversityJul 22, 2026
    Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion TreatmentConberceptPhase 4RecruitingFirst Affiliated Hospital of Chongqing Medical UniversityAug 21, 2025
    Aqueous Humor Proteome in Retinal Vein Occlusion With Macular EdemaConbercept—Active, not recruitingTianjin Medical University Eye HospitalAug 6, 2025
    Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity TherapyConberceptNot applicableRecruitingWang YushengDec 5, 2024
    Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic RetinopathyConberceptPhase 4Active, not recruitingShanghai Eye Disease Prevention and Treatment CenterMar 12, 2024

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1697671, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P49763, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.